Nucleotrace is a proprietary limited company registered in Australia, ACN 611 778 271. 

Contact Icon.png

©2019 by Nucleotrace

 
News

Nucleotrace awarded highly competitive grant from the Victorian Medical Research Acceleration Fund for work on cannabis and pharmaceuticals.

Nucleotrace takes out multiple awards at  Tech23 in Sydney, including -

 

  • The Innovation Excellence Award for the company whose technology demonstrates the highest level of innovation and originality

 

  • The Addison's Award for the most backable team

 

  • The Deep Technology Award presented by Cicada Innovations

Focus Applications
Pharmaceuticals

Counterfeit pharmaceuticals are responsible for one million deaths and cost the industry $100 billion each year. Nucleotrace has developed the first product-integrated supply chain monitoring technology for pharmaceuticals that tracks each ingredient over its entire life cycle. Information such as the batch number, expiry date and manufacturing facility is stored inside each tablet as a non-toxic molecular fingerprint.

Ammunition

Firearms are responsible for 41% of non-conflict homicides worldwide. Approximately 57% of these incidents go unsolved. Nucleotrace ammunition fingerprinting leaves an unbroken chain of identification on the user, gun and victim. This offers the capacity to identify a suspect from a victim's bullet entry wound alone, recover a molecular history of ammunition previously used in a firearm, and trace 3D-printed gun crime.

 
 
Competitive advantage

Unlike other DNA-tagging systems that are restricted to authentication application, our system is designed to identify an unknown set of DNA fragments from a pool of billions. We can also track multiple ingredients throughout a supply chain. This opens a wide range of novel applications including supply chain monitoring, counterfeit goods identification and random access for DNA-based archival data sotrage

We have also designed out encoding systems and chemistry around the most recent advances in DNA sequencing technology. In 2002 it took a room of equipment and cost $100M to sequence the human genome. Today it can be done on a handheld device for less than $500.

Nucleotrace technology is built for new, portable, real-time DNA sequencing technology:

Year: 2002

Cost: $100M

Req: 1 BUILDING

Year: 2010

Cost: $80k

Req: 1 ROOM

Year: 2015

Cost: $5k

Req: 1 LAPTOP

Year: 2019

Cost: $500

Req: 1 SMARTPHONE

Advantages: pharmaceuticals

Secure. Nucleotrace technology creates an immutable link between product, package and database (centralized,  decentralized or distributed).

Safe. Very small amounts of DNA oligonucleotide are used which is pharmacologically inactive and whose safety is supported by existing literature and safety data.

Inexpensive. We estimate that our technology is economically viable for cheap generic drugs

Coverage. 100% unbroken supply chain coverage from raw ingredients to finished product.

Tracing resolution. Traceability to the smallest unpackaged dosage unit (tablet), not just package.

Harmonised data sharing. Information transfers are harmonised between product ingredients, finished product, package and single point of contact (SPOC) database.

Rapid parallel sample processing. Up to 200 product samples can be processed in <1.5 hours which is suitable for auditing at points of sale and ports of entry.

Portable testing. Compatibility with new DNA sequencing technology will soon permit real-time smartphone based sample processing without the need for laboratory access.

Product-integrated information. When a product is mixed or split information is automatically merged or forked. 

Simple. Removes burden on moving parts of supply chain (e.g. individuals responsible for commissioning / decommissioning serial numbers – in the case of product serialization).

Forensic capabilities. Last legitimate node traceback permits identification of leaking/fraudulent nodes from product alone (e.g. products sold illegally, recombined/used in illicit drugs).